VIDEO: Quality metrics top issues that matter most to nephrologists, patients
Click Here to Manage Email Alerts
Key takeaways:
- Quality metrics in nephrology contain too many discrepancies between programs, according to Giullian.
- He said the End-Stage Renal Disease Treatment Choices, or ETC, model is not working.
SAN DIEGO — In this video exclusive from ASN Kidney Week, Jeffrey Giullian, MD, MBA, FASN, chief medical officer of DaVita, discusses three pressing regulatory issues for nephrology stakeholders.
“I give a lot of credit to the team at CMS. I know that what they’re trying to do is in the patients’ best interest, and yet there are some areas that are fairly frustrating,” Giullian, who is also a Healio | Nephrology News & Issues Editorial Advisory Board member, said.
Giullian described the “disconnect” between transplant quality metrics for the clinical team and for the transplant organizations and centers.
Although there is overlap in the large number of quality metrics, he said discrepancies exist.
“It really is time to come together as a community and define what quality means for patients in words that our patients would use,” Giullian said.
Giullian also said the End-Stage Renal Disease Treatment Choices, or ETC, model is not working to get patients on home dialysis or moving toward kidney transplantation.
Collapse
Click Here to Manage Email Alerts